Omalizumab Treatment in Patients with Severe Allergic Asthma

Tat T. S., ÇİLLİ A.

ISTANBUL MEDICAL JOURNAL, cilt.18, sa.3, ss.135-138, 2017 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 3
  • Basım Tarihi: 2017
  • Doi Numarası: 10.5152/imj.2017.93653
  • Dergi Adı: ISTANBUL MEDICAL JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.135-138
  • Anahtar Kelimeler: Asthma, omalizumab, severe allergic asthma, uncontrolled allergic asthma, QUALITY-OF-LIFE, REAL-LIFE, ANTIBODY OMALIZUMAB, MODERATE, TOLERABILITY, MALIGNANCY, EFFICACY, THERAPY, SAFETY
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Introduction: Omalizumab is a monoclonal antibody used for treating patients with severe allergic asthma. It has has been shown to be effective and is being increasingly used. This study aimed to evaluate the long-term efficacy and safety of omalizumab treatment in patients with severe allergic asthma.